Navigation Links
VIA Pharmaceuticals Complies With NASDAQ Rule
Date:3/28/2008

SAN FRANCISCO, March 28 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit report included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and filed with the Securities and Exchange Commission on March 28, 2008 contained an explanatory paragraph relating to the Company's ability to continue as a going concern. The disclosure in this press release is required under the above NASDAQ rule and does not represent any change to the Company's Annual Report on Form 10-K filed on March 28, 2008 with the Securities and Exchange Commission.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
2. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
3. SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
4. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
5. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
6. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
7. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
8. SGX Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
9. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
10. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
11. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , October 30, 2014 ... Holdings Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: ... ), Synthetic Biologics Inc. (NYSE MKT: SYN), and Ironwood ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,549.23, down 0.33%, the Dow Jones Industrial ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 ... collaboration provider, offers Office 365 end users the ... a complete phone system by adding voice enablement ... (O365) includes Lync Online, a communication tool that ... calls. With hosted voice, O365 becomes a comprehensive ...
(Date:10/30/2014)... Erlanger, Kentucky (PRWEB) October 30, 2014 Avure ... of the 525L, the newest member of its fleet of ... to be reaching an anniversary as we return to PackExpo ... a year ago in Las Vegas,” said Jeff Williams, CEO ... extremely well, and we’re pleased to be meeting the challenges ...
(Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... , , , SUNNYVALE, ... leader in the field of radiosurgery, announced today that its management is scheduled ... City on Thursday, September 10, 2009 at 11:00 a.m. ET (8:00 a.m. PT). ... available online from the investor relations page of the Company,s Web site at ...
... ... its national print advertising campaign for Cobroxin, the first clinically proven, over-the-counter treatment for ... will run in Arthritis Today, Prevention, Health, Star, Woman,s World, Soap Opera, and Self ... (Vocus) ...
... , CAMBRIDGE, Mass., Sept. 3 Idenix ... management will present a corporate overview at the upcoming Thomas ... at 10:55 a.m. ET at the Four Seasons Hotel in ... Conference on Monday, September( )14, 2009 at 3:55 p.m. ET ...
Cached Biology Technology:Accuray Incorporated to Present at Robert Baird 2009 Healthcare Conference 2Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain 2
(Date:10/29/2014)... research presented at the Society for Integrative Oncology ... for the first time that it is possible ... readily available nutritional supplement, AHCC. ... Smith, Pharm.D., associate professor in the Department of ... of Texas Health Science Center at Houston (UTHealth) ...
(Date:10/29/2014)... overwhelming number of chemicals from household and industrial products ... our bodies. But for most of them, scientists have ... they,ve taken the first step toward doing that by ... Their new method is published in the ACS journal ... Wambaugh and colleagues note that the risks to human ...
(Date:10/29/2014)... in German . ... and Peter Schlögelhofer at the Max F. Perutz Laboratories ... University of Vienna dived into the process of meiosis ... display an inversion of the standard meiotic phases. The ... Nature Communications . , Meiosis is the two-step ...
Breaking Biology News(10 mins):HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Meiotic cell division 'the other way round' 2
... Molecular Imaging Labs (MI Labs) have succeeded in combining ... of equipment. These techniques are particularly useful for cancer ... microSPECT. SPECT and PET can be performed simultaneously and ... microPET. The new device is known as the VECTor ...
... Properties SA announces the winners of the Reaxys PhD ... PhD or having completed a PhD within the last ... the fields of organic, organometallic and inorganic chemistry. ... launched in January 2010. Submissions consisted of a representative ...
... Navarra, the Polytechnic University of Madrid (CBGP), the University ... Institute of Agricultural Research have managed to sequence the ... olive tree. The study, included in the June issue ... of the genome of a pathogenic bacteria undertaken in ...
Cached Biology News:TU Delft and MI Labs merge PET and SPECT biomedical imaging techniques and increase resolution 2The Reaxys Ph.D. Prize awards innovative research in organic, organometallic and inorganic chemistry 2The Reaxys Ph.D. Prize awards innovative research in organic, organometallic and inorganic chemistry 3Genome of bacteria responsible for tuberculosis of olive tree sequenced 2
...
Fetal Calf Serum Replacement (Bistec) serum...
NEWBORN CALF SERUM AND PLASMA...
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Biology Products: